|
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALDH1-positive tumor and stromal cells were detected in 33% and 41% of hormone naive lymph node metastases (n = 63), 52% and 24% of castration resistant bone metastases, as well as 89% and 28% of castration resistant visceral metastases (n = 21), respectively.
|
30287243 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed a significant association between increasing ALDH1 expression and International Federation of Gynecology and Obstetrics stage (OR 2.02, 95% CI 1.16-3.52), lymph node metastasis (OR 1.91, 95% CI 1.01-3.61), and distant metastasis (OR 5.43, 95% CI 1.44-20.42) in OC.
|
29662319 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with CRC, increased expression of the ALDH1A1 protein was significantly associated with the presence of lymph node metastasis: 64.28% in N0 cases; 75.49% in N1 cases; and 82.14% in N2 cases, (P=0.002).
|
29748529 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Samples classified as mesenchymal (post-EMT) showed elevated expression of CSCs markers (OCT-4 and CD44 in PT; OCT-4 in LNM; ALDH1, OCT-4, NANOG, CD44 in CTCs).
|
29660692 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of VM, ALDH1 and MVD were positively associated with invasion of depth, lymph node metastasis (LNM), distant metastasis and tumor-node-metastasis (TNM) stages, and negatively with patients' overall survival (OS).
|
28431527 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ALDH1 expression correlated significantly with lymph node metastases (p = 0.048) and the Ki-67 labeling index (p < 0.001) in the early recurrence group.
|
27368476 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ALDH1A1(high) expression or β-catenin(c) expression alone was associated with lymph node metastasis, and worse clinical outcome in breast cancer patients, especially in patients receiving cyclophosphamide treatment.
|
26398662 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ALDH1A1 expression was significantly associated with the presence of LC; lymph node metastasis, clinical stage and differentiation in LC and BC; and molecular subtype in BC (p < 0.05).
|
26230297 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The percentage of positive musashi-1 and ALDH1 expression were significantly lower in patients identified with clinical stage I or II ovarian adenocarcinomas without lymph node metastasis compared to patients with clinical stage III or IV tumors and lymph node metastasis.
|
25971681 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The overall analysis showed that higher expression of ALDH1A1 is associated with larger tumor size, higher histological grade, greater possibility of lymph node metastasis (LNM), higher level expression of epidermal growth factor receptor 2 (HER2), and lower level expression of estrogen receptor (ER)/progesterone receptor (PR).
|
24938375 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, ALDH1A1 overexpression was associated with poor prognosis in patients subgroups stratified by tumor size, depth invasion and lymph node metastasis.
|
25253129 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Positive ALDH1A1 expression was correlated with patients' smoking status (p = 0.022), lymph-node metastasis (p = 0.006), clinical stage (p = 0.004), and a decreased overall survival time (p < 0.001).
|
22617249 |
2012 |